Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | STK17A | Q9UEE5 | 4/20 | 0.55 |
| ▸ | STK17B | O94768 | 3/20 | 0.55 |
| ▸ | EGFR | P00533 | 5/20 | 0.52 |
| ▸ | IGF1R | P08069 | 1/20 | 0.47 |
| ▸ | SYK | P43405 | 1/20 | 0.46 |
| ▸ | RAPGEF4 | Q8WZA2 | 1/20 | 0.42 |
| ▸ | CDK5 | Q00535 | 3/20 | 0.41 |
| ▸ | CDK5R1 | Q15078 | 3/20 | 0.41 |
| ▸ | CCNA2 | P20248 | 2/20 | 0.41 |
| ▸ | CDK2 | P24941 | 2/20 | 0.41 |
| ▸ | CDK1 | P06493 | 1/20 | 0.41 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | INSR | P06213 | 1/20 | 0.41 |
| ▸ | ALK | Q9UM73 | 1/20 | 0.41 |
| ▸ | LCK | P06239 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5413388 | 0.80 | GSK3B (0.51) | STK17ASTK17BEGFRIGF1RCDK5 | |
| SCHEMBL5405530 | 0.79 | L3MBTL1 (0.57) | STK17ASTK17BSYKULK1 | |
| SCHEMBL5402321 | 0.77 | STK17A (0.55) | STK17ASTK17B | |
| SCHEMBL13788949 | 0.77 | STK17A (0.50) | STK17ASTK17BEGFRIGF1RSYK | |
| SCHEMBL4496644 | 0.76 | EGFR (0.50) | STK17ASTK17BEGFRRAPGEF4LCK | |
| SCHEMBL5414003 | 0.75 | JAK2 (0.56) | STK17ASTK17BSYK | |
| SCHEMBL10187807 | 0.75 | STK17A (0.61) | STK17ASTK17BEGFRSYKCDK5 | |
| SCHEMBL5413853 | 0.75 | JAK2 (0.68) | STK17AEGFRIGF1RSYKCDK5 | |
| SCHEMBL5402411 | 0.74 | SYK (0.61) | EGFRIGF1RSYKCDK1 | |
| SCHEMBL26506369 | 0.73 | CHEK1 (0.54) | SYKULK1INSRALK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7166599-B2 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2007-01-23 | — | — | US | disclosed |
| US-20050090486-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2005-04-28 | — | — | US | disclosed |
| EP-1453516-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | Boehringer Ingelheim Pharma GmbH & Co.KG (DE) | 2004-09-08 | — | — | EP | disclosed |
| US-20030134838-A1 | Trisubstituted pyrimidines | BOEHRINGER INGELHEIM PHARMA KG (DE) | 2003-07-17 | — | — | US | disclosed |
| WO-2003032994-A2 | NOVEL TRI-SUBSTITUTED PYRIMIDINES, METHOD FOR PRODUCTION AND USE THEREOF AS MEDICAMENT | BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG (DE) | 2003-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030134838-A1 | Trisubstituted pyrimidines | APP, PSEN1, BACE1 | STK17A 3301/4885STK17B 3455/4885EGFR 3316/4885 |
| US-20050090486-A1 | Trisubstituted pyrimidines | APP, BACE1, PSEN1 | STK17A 3456/4885STK17B 3502/4885EGFR 3952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.